TNGX Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -4.78%, SMA50 -1.49%, SMA200 50.44%). The stock’s 14-day RSI is 44.65 (neutral), while the ATR of 0.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.95% below its high and over 737.86% above its low. Average 10-day trading volume of 2.02 million shares is below the 3-month average of 3.16 million, indicating normal recent market interest.

Tango Therapeutics, Inc. has 111.26 million shares outstanding. The public float is 37.40 million shares, elevated short interest at 27.39% of float. This equals 25.40 million shares. The short ratio is 14.56 days. Institutional investors hold 125.55% of the float. Insiders own 12.26%. Third Rock Ventures IV, L.P. holds 13.39 million shares, Boxer Capital, LLC has 8.20 million shares and Davis Aaron I. has 7.12 million shares. Over the past six months, insider transactions show net selling. They sold 3.47 million shares across 7 transactions.

Tango Therapeutics, Inc. generated EPS of -$0.92 over the past year. Five-year average earnings growth is 7.47%. Wall Street analysts project EPS growth of -4.76% annually over the next five years. The latest quarter delivered EPS of $0.13. The next quarter is forecast at -$0.32. Next year's EPS is expected at -$24.59. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $15.00 to $10.00. The high target offers 73.81% upside. The low target suggests 15.87% downside. The mean target is $12.40. This offers 43.68% upside. Tango Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 1249.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -29.41% in August 07, 2024.

Tango Therapeutics, Inc. trades at a P/E ratio of -9.57, slightly below the S&P 500 average, with a price-to-sales ratio of 14.4 and a price-to-book ratio of 6.01 trading at moderately above to book value. The P/FCF stands at -6.53, also above market averages.

Tango Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.95. This means the shares are trading below this model’s fair value.

Tango Therapeutics, Inc. (NASDAQ:TNGX) closed at $8.63 USD, losing -$0.12 (-1.37%) from the previous close of $8.75. The stock is currently mid-range between its 52-week high and low $1.03 and $11.20. With a market capitalization of about $953.33 million, Tango Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.72). Key stats such as the average daily volume over the past year has been around 3.17 million shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, Tango Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Barbara L. Weber, the company employs approximately 155 people and listed since September 03, 2020. Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer.

Our AI price prediction model suggests that Tango Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.43%, with price expected at $8.84 by January 13, 2026, within a range of $7.74 to $9.93 3-Month Outlook: Projected fall of -47.39%, reaching $4.54 by March 27, 2026, with a range of $4.12 to $4.95. 1-Year Outlook: Projected gain of 247.74%, with price at $30.01 by December 30, 2026, within a range of $31.66 to $32.68.

Tango Therapeutics, Inc. (NASDAQ:TNGX) shares are up 179.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Tango Therapeutics, Inc. trading at a premium to the broader market with a P/E of -9.57. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $14.43, suggesting 67.21% upside. Our AI forecast model points to short-term strength (2.43% over two weeks), a medium-term fall (-47.39% over three months), and a longer-term gain (247.74% over one year), with expected trading ranges indicating moderate volatility.